ESR1 and breast carcinoma: The clinical relevance of our data regarding repurposing TKIs as ferroptosis inducers is strengthened by recent findings based on the functional analysis of breast cancer cell lines that demonstrate that TNBCs are enriched in ferroptosis gene signatures and are vulnerable to ferroptosis inducers, compared to other breast cancer subtypes, i.e., ER-positive and/or HER2-positive subtypes [137].